XML 23 R6.htm IDEA: XBRL DOCUMENT v3.26.1
CONSOLIDATED STATEMENTS OF CASH FLOWS
¥ in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2025
CNY (¥)
Dec. 31, 2025
USD ($)
Dec. 31, 2024
CNY (¥)
Dec. 31, 2023
CNY (¥)
CASH FLOWS FROM OPERATING ACTIVITIES        
Net loss ¥ (379,420) $ (54,256) ¥ (652,075) ¥ (531,021)
Adjustments to reconcile net loss to net cash generated from operating activities:        
Depreciation of property, plant and equipment (note 10) 103,508 14,801 84,775 82,124
Amortization of intangible assets (note 13) 36,122 5,165 36,355 36,705
Amortization of land lease payments (note 11) 9,626 1,376 9,627 9,625
Lease expense to reduce operating lease ROU 14,810 2,118 22,578 26,683
Income from equity method investments (13,047) (1,866) (12,696) (20,789)
Change in fair value of derivative liability     (166) (5,207)
Changes in fair value of short-term investments     (7,290)  
(Gain) loss on disposal of long-lived assets 2,097 300 13,110 (62)
Deferred tax expense (benefit) (7,868) (1,125) (15,652) (13,039)
Allowance for doubtful accounts, net (6,880) (984) 128,196 64,712
Impairment of long-term investments 22,160 3,169    
Provision of Inventory write down 52 7    
Interest and consultation expenses 152,326 21,782 193,199 165,669
(Gain) Loss on disposal of subsidiaries (note 4)     (48,497) 638
Gain on sale of partial interests in equity method investment (37,471) (5,358) 120 (37,498)
Changes in operating assets and liabilities net of effects of acquisition and disposals:        
Accounts receivable 6,145 879 12,018 36,454
Prepayments and other current assets 161,280 23,063 (335,657) (149,738)
Inventories (12,576) (1,798) 6,498 44,489
Other non-current assets (958) (137) (458) 1,618
Accounts payable (122,288) (17,487) 93,052 15,779
Accrued expenses and other liabilities (165,598) (23,680) 97,497 70,838
Deferred revenue 39,534 5,653 (3,089) (41,179)
Income tax payable 5,946 850 101 705
Accrued unrecognized tax benefit 6,594 943 35 (15,830)
Operating lease liabilities (15,918) (2,276) (19,330) (18,147)
Net cash used in operating activities (201,824) (28,861) (397,749) (276,471)
CASH FLOWS FROM INVESTING ACTIVITIES        
Investment in equity investments without readily determinable fair value       (100)
Acquisitions of property, plant and equipment (56,322) (8,054) (150,772) (113,003)
Acquisitions of intangible assets (30) (4) (10,160) (4,211)
Deposits for the purchases of property, plant and equipment (34,982) (5,002) (249,902) (2,699)
Proceeds from disposal of property, plant and equipment 7,501 1,073   310
Proceeds from disposal of subsidiaries (10) (1) 9,057  
Proceeds from dividend 3,188 456    
Cash distribution from equity method investments     10,000 12,022
Investment in a joint venture     (102,000)  
Proceeds from disposal of other investment     27,664  
Purchase of short - term investment 134,620 19,250 (204,607)  
Proceeds from disposal of short - term investment     77,276  
Proceeds from disposal of certain percentage of an equity method investment       60,000
Net cash provided by/(used in) investing activities 53,965 7,718 (593,444) (47,681)
CASH FLOWS FROM FINANCING ACTIVITIES        
Proceeds from short-term bank borrowings 359,226 51,369 654,699 337,695
Proceeds from long-term bank and other borrowings 94,825 13,560 1,767,174 110,000
Borrowings from related parties (note 25) 517,000 73,930 300,543 22,150
Repayment to related parties (note 25) (468,410) (66,982) (335,359) (61,777)
Repayment of short-term bank and other borrowings (437,061) (62,499) (360,329) (442,858)
Repayment of long-term bank and other borrowings (433,538) (61,995) (1,391,219) (7,561)
Capital injection from a noncontrolling interests in a subsidiary 60,999 8,723   300,004
Proceeds from initial public offering of Concord Healthcare Group Co., Ltd. 504,191 72,098 510,522 0
Net cash generated from financing activities 197,232 28,204 1,146,031 257,653
Effect of foreign exchange rate changes on cash and cash equivalent and restricted cash 12,353 1,766 (8,275) (2,425)
Net increase (decrease) in cash 61,726 8,827 146,563 (68,924)
Cash and cash equivalents and restricted cash at beginning of the year 236,982 33,888 90,419 159,343
Cash and cash equivalents and restricted cash at end of the year 298,708 42,715 236,982 90,419
Reconciliation of cash and cash equivalents and restricted cash to the consolidated balance sheets:        
Cash and cash equivalents 297,787 42,583 216,224 58,139
Restricted cash, current portion 921 132 20,758 32,280
Restricted cash, noncurrent portion       0
Total cash and cash equivalents and restricted cash 298,708   236,982 90,419
Supplemental schedule of major cash flows information:        
Income tax paid (109) (16) (148) (898)
Interest paid (182,986) (26,167) (188,304) (152,359)
Supplemental schedule of major non-cash activities:        
Acquisition of property, plant and equipment, construction in progress and other intangible assets through utilization of deposits 757 108 ¥ 79,644 5,812
Acquisition of property, plant and equipment, construction in progress and other intangible assets included in accrued expense and other liabilities       285,358
Acquisition of property, plant and equipment, construction in progress and other intangible assets included in other long-term liabilities ¥ 10,350 $ 1,480   ¥ 0